Background Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs)
versus oral antipsychotics for schizophrenia has been inconsistent across study designs …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs)
should improve medication adherence and reduce relapses in schizophrenia. However …

Abstract Background Real-World Data (RWD) studies provide important insights in disease
epidemiology, in real clinical populations, with long follow-up periods. The aim of the …

Introduction We see a development in the field of long-acting products to serve patients with
chronic diseases by providing benefits in adherence, efficacy, and safety of the treatment …

Introduction: Many patients with schizophrenia exhibit difficulties in maintaining adherence
to oral antipsychotics, calling for more reliable drug delivery systems. Areas covered: While …

BackgroundPaliperidone palmitate is one of the most widely prescribed long-acting
injectable (LAI) antipsychotics in the UK. However, it is relatively expensive and there are …

The course of schizophrenia is characterized by multiple relapses, incomplete remission of
symptoms, enduring cognitive deficits, and social and occupational functional impairments …

The aim of the study was to summarize the efficacy and tolerability of paliperidone palmitate,
an atypical long-acting antipsychotic drug. Paliperidone is a 9-hydroxy metabolite of …